CARMEL HENSLEY: Open Payments
NPI 1174918544 · LONDON, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,770 in 94 payments from 30 companies in 2025. Trend: 2023 $1,420 · 2024 $890 · 2025 $1,770
Food & beverage: $1,686Education: $84
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 25 | $392 |
| Lundbeck LLC | 9 | $251 |
| Novo Nordisk Inc | 12 | $146 |
| Janssen Biotech, Inc. | 3 | $117 |
| Phathom Pharmaceuticals, Inc. | 5 | $102 |
| Madrigal Pharmaceuticals | 3 | $77 |
| Novartis Pharmaceuticals Corporation | 4 | $67 |
| UCB, Inc. | 3 | $63 |
| Alexion Pharmaceuticals, Inc. | 2 | $51 |
| Biogen, Inc. | 2 | $49 |
Products named: VYEPTI, VRAYLAR, VOQUEZNA, LINZESS, REZDIFFRA, QULIPTA, Ozempic, LEQVIO.
Industry payments across KY — which companies pay providers there.
